Unlike FDA-approved drugs, compounded tirzepatide won’t come with a package insert when the prescription is dispensed. It’s important to discuss using compounded tirzepatide with a doctor ...

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

"The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for ...

Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years. At the end of this period, the results were impressive. On average, participants lost ...

Participants given tirzepatide lowered their HbA1c by a mean 0.77% more than those given a higher dulaglutide dose. More tirzepatide participants hit a weight loss threshold known for disease ...

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes ...

Late last year, the FDA approved tirzepatide (Zepbound, Eli Lilly) for adults with moderate to severe obstructive sleep apnea and obesity after the medication showed significantly more efficacy vs.

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least 3 years in adults with overweight or obesity who do not have diabetes, according to ...